identifying novel digital measures for fatigue and sleep disturbances that will provide more objective, sensitive and reliable measures of the severity and impact of these symptoms in the person’s normal surrounding.
one year longitudinal study with approximately 2000 subjects will be conducted
Participants with neurological or immunological disorders from various countries will be screened and recruited
Participants with neurological or immunological disorders from various countries will be screened and recruited
All participants will be given a combination of 2-4 digital devices for use in their own environment for several periods
Data on fatigue, sleep, selected activities of daily living and other relevant contextual information will be collected by smartphone several times a day while using the devices
In order to establish which devices are suitable for use, complex data analysis will be performed
The devices that met the criteria will be considered for future use in clinical trials
The novel clinically validated digital endpoint will be able to:
There is a growing focus on monitoring health in uncontrolled (aka in-the-wild) settings. This is partially due to the limitations of occasional formal assessments, and to the increasing availability of off-the-shelf sensing devices and applications.
Touch data, and in particular text-entry data, has been predominantly collected in laboratory settings, under controlled conditions. While touch and text-entry data has consistently shown its potential for monitoring and detecting a variety of conditions
Fatigue and sleep disturbances are symptoms of several chronic diseases associated with poor quality of life and increased healthcare costs. A large part of measuring patient’s health is using self-reported methods that can be prone
During the Sjogren Europe & the BSSA live webinar, the IDEA-FAST project’s scientific coordinator – professor Wan Fai Ng (Newcastle University) presented about chronic fatigue. Chronic fatigue is one of the most prevalent and debilitating
On 27 Sep 2021, the IMI Consortium IDEA-FAST submitted a request for an initial CHMP (Committee for Medical Products for Human Use) qualification advice to discuss the results of the Feasibility Study and acceptability of
One of the ways we ensure that the patient voice is heard and put at the centre of the project in all its stages is by having monthly meetings with representatives of several patients organisations in
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853981. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and PARKINSON’S DISEASE SOCIETY OF THE UNITED KINGDOM LBG.
